Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
According to IQVIA sales data for the 12-month period ending November 2021, the Ziac tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately US $ 30.3 million
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
The company has 47 ANDA's pending approval with the U.S.FDA
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
Subscribe To Our Newsletter & Stay Updated
